This review evaluates the role of nucleic acid sensing pathways — chiefly cGAS–STING, AIM2, and endosomal Toll-like receptors (TLRs) — in kidney disease, covering both acute kidney injury (AKI) and chronic kidney disease (CKD) across glomerular and tubular compartments, and catalogues the therapeutic landscape targeting these pathways.
Mislocalized self-nucleic acids (mitochondrial DNA, nuclear DNA fragments, reactivated endogenous retroelements) activate cGAS–STING, AIM2, and TLR pathways in podocytes, tubular epithelial cells, mesangial cells, and infiltrating immune cells, driving inflammation, fibrosis, and cell death across multiple kidney disease contexts. Therapeutic agents range from FDA-approved hydroxychloroquine (TLR7/9) to preclinical STING antagonists (H-151, C-176, LB244) and a Phase 2 cGAS inhibitor (VENT-03) in active cutaneous lupus.
This is a narrative review without systematic search methodology or meta-analysis, so conclusions reflect the authors' synthesis rather than pooled quantitative data. Most mechanistic evidence comes from mouse models, with limited human clinical trial data specifically in kidney endpoints. The therapeutic table includes agents at very early preclinical stages alongside approved drugs, making direct comparison of efficacy difficult.
Clinicians managing lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, or AKI should be aware that cGAS–STING and TLR-driven sterile inflammation are active therapeutic targets, with several agents in Phase 2 trials (baricitinib, anifrolumab, VENT-03). Mitochondrial protection strategies (e.g., elamipretide) that limit mtDNA leakage represent an upstream approach to dampening innate immune activation in the kidney.